Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

Keyword: brca

11 through 20 of 119

Relevance: Medium

Strength of Science: Medium

Research Timeline: Animal Studies

View Related Clinical Trials

Study : Weight may affect breast cancer risk in women with an inherited BRCA mutation

Relevance: Medium

Strength of Science: Medium

Research Timeline: Animal Studies

View Related Clinical Trials

Most relevant for: People with an inherited mutation in BRCA1 or BRCA2 concerned about their breast cancer risk

A study that looked at normal breast cells from women with an inherited BRCA mutation found more DNA damage among women who were overweight (based on a measurement known as body mass index) than those who were not overweight. The results suggest that maintaining a lower weight may reduce breast cancer among this high-risk population. (Posted 3/30/23)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Human Research

View Related Clinical Trials

Study : Promising early results for treating metastatic prostate cancer

Relevance: Medium-High

Strength of Science: High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with metastatic castration-resistant prostate cancer (mCRPC)

The TALAPRO studies looked at how well the oral drug Talzenna (talazoparib) works as a treatment for metastatic castration-resistant prostate cancer (mCRPC). The addition of Talzenna to treatment with Xtandi (enzalutamide) increased the time until the cancer got worse or came back (progression-free survival). The greatest benefit was seen in people who had an inherited or tumor mutation in a gene that repairs DNA damage (such as ATM, BRCA1, BRCA2 and others). (Posted 3/1/23)

Update: On June 20, 2023, the Food and Drug Administration (FDA) approved the combination of Talzenna with Xtandi as an initial treatment for some people with mCRPC for people with inherited or tumor mutations in genes that repair DNA damage. 

Este artículo está disponible en español.

Read More

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Frequent aspirin use may reduce the risk of ovarian cancer

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Healthy people at high-risk of ovarian cancer.

Aspirin may help lower the risk of ovarian cancer in people who have a high risk of the disease, according to a new analysis of 17 studies. While other preventive strategies have been found to more effectively lower the likelihood of developing ovarian cancer in high-risk women, taking aspirin daily or almost daily may reduce a person’s risk of developing ovarian cancer by 13 percent. The benefit was greater among people with additional risk factors for the disease. (Posted 2/22/23)

Este artículo está disponible en español.

Read More

Relevance: Medium

Research Timeline: Human Research

View Related Clinical Trials

Update : Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations

Relevance: Medium

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with a BRCA1 or PALB2 mutation undergoing prophylactic bilateral mastectomy

A new vaccine was first tested on people diagnosed with triple-negative breast cancer. The vaccine is now being tested to prevent breast cancer among people with an inherited mutation in BRCA1 or PALB2 who are at high risk and who are planning to have a risk-reducing mastectomy. (Posted 1/9/23) Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

Study : Male breast cancer: Patient and surgeon experiences

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

Most relevant for: Men with breast cancer

By surveying male breast cancer patients and the surgeons who treat them, researchers gained insight into the experiences of both groups, shedding light on an important issue for men with breast cancer. (Posted 12/22/22)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Prostate cancer screening may benefit people with Lynch syndrome

Relevance: High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with Lynch syndrome

Initial results from the IMPACT trial show that PSA testing to screen for prostate cancer in people with Lynch syndrome can detect aggressive early prostate cancers. These findings support the use of PSA screening in men with Lynch syndrome, particularly men with an inherited mutation in an MSH2 or MSH6 gene. (Posted 11/10/22)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Study : More is not better: PARP dose can be safely reduced for people with ovarian cancer

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People taking a PARP inhibitor for ovarian cancer maintenance therapy

Maintenance therapy with a PARP inhibitor is now the standard of care for many people with advanced or recurrent ovarian cancer. However, PARP inhibitors may have significant side effects. This study shows that reducing the dose of a PARP inhibitor does not affect survival. (Posted 11/8/22)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Study : Teens and young adults respond well to learning about familial cancer risk

Relevance: Medium-High

Strength of Science: Medium-High

Most relevant for: Mothers who have had genetic testing for BRCA1 or BRCA2 whether or not they have been diagnosed with breast or ovarian cancer

Little is known about how awareness of hereditary cancer in a high-risk family affects the quality of life of teens and young adults. This study looked at the lifestyle choices, cancer awareness and quality of life of adolescents and young adults whose mothers had undergone testing for a BRCA mutation. (Posted 10/11/2022) Este artículo está disponible en español.

Read More

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Update : PARP inhibitors withdrawn as third-line or later treatment for recurrent ovarian cancer

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: people with recurrent ovarian cancer who have received 3 or more prior lines of treatment and who have an inherited or tumor mutation in BRCA1 or BRCA2 or whose tumor is HRD positive

Survival data from a clinical trial signaled that PARP inhibitors may not work as well as chemotherapy for patients with recurrent ovarian cancer who have received three or more lines of treatment. As a result, FDA approvals have been withdrawn for PARP inhibitors in this setting.  This does not affect PARP inhibitor approvals for use as maintenance therapy for ovarian cancer. (Posted 10/4/22)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in BRCA2.

This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors.  (posted 9/6/2022)

Este artículo está disponible en español.

Read More